Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 15/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 13/20 | 0.42 |
| ▸ | PDE4A | P27815 | 3/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.42 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5477358 | 0.92 | PDE4B (0.49) | PDE4DPDE4BPDE4APDE4CROCK2 | |
| SCHEMBL5481132 | 0.91 | PDE4D (0.48) | PDE4DPDE4BPDE4APDE4CFNTA | |
| SCHEMBL5481937 | 0.91 | PDE4D (0.42) | PDE4DPDE4BPDE4APDE4CFNTA | |
| SCHEMBL5481129 | 0.90 | PDE4D (0.39) | PDE4DPDE4BPDE4APDE4CFNTA | |
| SCHEMBL2545779 | 0.87 | PDE4D (0.41) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL2349881 | 0.85 | PDE4D (0.42) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL5482662 | 0.83 | PDE4D (0.57) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL2341323 | 0.83 | PDE4A (0.39) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL3471184 | 0.83 | PDE4D (0.49) | PDE4DPDE4BPDE4APDE4C | |
| Hydrochloric Acid SCHEMBL3470610 | 0.82 | PDE4D (0.48) | PDE4DPDE4BPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185149-A1 | Novel amido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibtors | ALTANA PHARMA AG (DE) | 2007-08-09 | — | — | US | disclosed |
| EP-1725534-A1 | NOVEL AMIDO-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | Altana Pharma AG (DE) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005087745-A1 | NOVEL AMIDO-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185149-A1 | Novel amido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibtors | PDE4A, PDE4B, PDE4C | PDE4D 4/4885PDE4B 2/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.